Posted inClinical Updates Dermatology Pediatrics
Dupilumab Enhances Growth and Bone Health in Pediatric Severe Atopic Dermatitis: Insights from a Phase 3 Trial
Dupilumab treatment in children aged 6–11 with severe atopic dermatitis is associated with significant improvements in linear growth and bone biomarker levels over one year, suggesting benefits beyond skin clearance.
